TB-500 is one of the most searched names in recovery-focused peptide research, and also one of the most misunderstood. The short version: TB-500 is the name commonly used for synthetic material based on thymosin beta-4, a naturally occurring peptide with a well-documented role in cell biology. Here is what the published record actually contains.
What thymosin beta-4 is
Thymosin beta-4 is a 43-amino-acid peptide found widely in human and animal cells. Its best-characterized job in the literature is actin regulation: it binds monomeric G-actin and acts as a major actin-sequestering molecule, which places it at the center of how cells assemble and remodel their cytoskeleton. Because actin dynamics underlie cell migration, that biology connects thymosin beta-4 to processes like tissue remodeling in the published research.
What the preclinical literature documents
The research base is dominated by preclinical work. Published studies have examined thymosin beta-4 in animal and cell-based models of dermal wound repair, corneal injury, and cardiac tissue, among others. Clinical investigation has been limited and narrow in scope, and no thymosin beta-4 product is an approved drug. As with much of the peptide field, the honest summary is that the cell biology is well established while the applied evidence remains preclinical.
Worth knowing for documentation purposes: thymosin beta-4 and its synthetic versions appear on the World Anti-Doping Agency prohibited list, which is one reason the compound is frequently discussed in sport-science contexts.
TB-500 versus thymosin beta-4
In catalog language, TB-500 generally refers to synthetic peptide material based on the thymosin beta-4 sequence or its active fragment. When you evaluate any supplier, the label name matters less than the paperwork: what the third-party certificate identifies, at what purity, for which lot.
Where it sits in our catalog
We stock TB-500 as part of our BPC-157 / TB-500 Blend (5mg / 5mg), pairing it with BPC-157 in a single lyophilized vial, and as a component of the four-peptide KLOW Blend. Each vial carries a printed lot number tied to our public COA ledger, where third-party certificates are published as testing completes. Lots awaiting certification are labeled pending. We do not publish results we do not have.
Quick answers
Is TB-500 the same molecule as thymosin beta-4? TB-500 is the common catalog name for synthetic material based on thymosin beta-4 or its active fragment. The certificate for a specific lot is what defines the material.
Is there human clinical evidence? Clinical investigation has been limited. The published evidence base is overwhelmingly preclinical, and no thymosin beta-4 product is an approved drug.
How do I verify a lot? Match the lot number printed on the label to its entry in the COA ledger.
For laboratory and in-vitro research use only.
For laboratory and in-vitro research use only. Not for human or veterinary use. See our research-use disclaimer.
